Системный медикаментозный тромболизис в лечении пациентов с ишемическим инсультом

1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001.
2. Суслина З.А., Пирадов М.А. Инсульт. Диагностика, лечение и профилактика. Руководство для врачей. М., 2008.
3. Суслина З.А. Очерки ангионеврологии. М., 2005.
4. Rha J-H, Saver JL. The Impact of Recanalization on Ischemic Stroke Outcome. A Meta-Analysis. Stroke 2007; 38: 967–73.
5. The Multicenter Acute Stroke Trial-Europe (MAST-E) Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–50.
6. The Multicentre Acute Stroke Trial-Italy (MAST-I) Study Group. Randomised controlled trial of Streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995; 346: 1509–14.
7. Donnan GA et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996; 276: 961–6.
8. Hacke W et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25.
9. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7.
10. Hacke W et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245–51.
11. Clark WM. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282 (21): 2019–26.
12. Wardlaw JM et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; CD000213.
13. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 2004; 363: 768–74.
14. Hacke W et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008; 359 (13): 1317–29.
15. Lees KR et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 2010; 375: 1695–703.
16. Wahlgren N et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Trrombolysis in Stroke-Monitoring Study (SIST-MOST): an observational study. Lancet 2007; 369: 275–82.
17. Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3–4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010; 9: 866–74.
18. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008: http://www.eso-stroke.org/recommendations
19. Adams H et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007; 38: 1655–711.
20. Wardlaw C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ 2003 (1); 326 (7383): 233–4.
21. Molina CA et al. Thrombolysis-related hemorrhagic infarction. A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002; 33: 1551–6.
22. Lansberg MG et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275–8.
23. Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинич. и экспер. неврол. 2007; 1: 17–22.
24. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6): 862–7.